Passage BIO, Inc. cotiza a 4.55 USD y tiene una capitalización bursátil de $15M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infanti…
| Periodo | 2026-08 | 2026-03 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-2.44 | — | $-4.09 | $-2.44 |
| Estimado | $-2.83 | $-2.80 | $-2.80 | $-2.97 |
| Sorpresa | +13.8% | — | -46.1% | +17.8% |
| Métrica | PASG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -242.7% | -40.4% | -202.3% |
| ROA | -73.1% | -32.0% | -41.1% |
| Current Ratio | 2.07 | 2.84 | -0.77 |
| Debt / Equity | — | 0.28 | — |